MEETING
the Challenge
Our Team is rapidly pursuing the diagnosis & treatment of chronic inflammatory diseases starting with Long Covid.
The FDA granted HealthBio the approval to proceed with our clinical trial in January, 2024.
This Double Blind Placebo Controlled Trial will begin patient enrollment in the coming weeks
for patients suffering from Long Covid symptoms. This combination therapeutic has potential to treat other immune-mediated disorders and diseases like ME-CFS, chronic Lyme and Fibromyalgia.
Our scientists, doctors and business leaders
are experienced in the fields of immunology, inflammation and oncology and are passionate
in delivering novel therapeutics to patients suffering from immune-mediated diseases.
MEET OUR TEAM
Executive & Clinical Leadership
TAP TEAM MEMBERS TO VIEW THEIR BIOS
Our Extended Team Expertise
INVESTMENT/
EQUITY FIRM
Biotech Expertise
MEDICAL
ADVISORY BOARD
Selected from national KOL Team
PUBLIC
RELATIONS FIRM
Biotech Launch
Expertise
MARKET ACCESS - PAYER / HEALTH PLAN
GPO / PAYER Launch
Expertise
MEDICAL/CRO
PROTOCOL EXPERTS
Experienced FDA
Submissions
LEGAL COUNSIL
M&A / Patent Expertise
Contact Our Team
One of our team members will get back to you
as soon as possible